ERAS · Erasca, Inc. · Executive Compensation
$13.61
-0.61 (-4.29%)
At close · Nov 20
Return incl. dividend (before tax)
Q4 2023 earnings call transcript
Market Cap
$4.78B
Shares
350.96M
Volume · Nov 20
11.07M
Avg daily vol (3M)
5.23M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Jonathan Lim | Chairman, Chief Executive Officer, and Co-Founder | $4,298,838 |
| David Chacko | Chief Financial Officer and Chief Business Officer | $1,778,496 |
| Shannon Morris | M.D., Ph.D. Chief Medical Officer | $1,750,898 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Jonathan Lim | Chairman, Chief Executive Officer, and Co-Founder | $3,894,032 |
| David Chacko | Chief Financial Officer and Chief Business Officer | $1,884,506 |
| Shannon Morris | M.D., Ph.D. Chief Medical Officer | $1,587,510 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jonathan Lim | Chairman, Chief Executive Officer, and Co-Founder | $5,407,446 |
| David Chacko | Chief Financial Officer and Chief Business Officer | $2,433,990 |
| Ebun S. Garner | General Counsel and Corporate Secretary | $2,021,760 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Jonathan Lim | Chairman, Chief Executive Officer, and Co-Founder | $7,523,335 |
| David Chacko | Chief Financial Officer and Chief Business Officer | $3,663,803 |
| Wei Lin | M.D .^ Former Chief Medical Officer | $2,906,267 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Wei Lin | M.D .^ Former Chief Medical Officer | $3,705,175 |
| Ebun S. Garner | General Counsel | $2,891,630 |
| Jonathan Lim | Chairman and Chief Executive Officer | $850,234 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Jonathan Lim | Chairman and Chief Executive Officer | $1,964,696 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Nicholas (Nik) Chetwyn, Ph.D. | Chief Operating Officer | Terminated | 2026-10-16 |
| Charles S. Fuchs, M.D., M.P.H. | President, Research & Development | Appointed | 2026-08-10 |
| Shannon R. Morris, M.D., Ph.D. | Chief Medical Officer | Appointed | 2023-04-10 |
| Jean Liu | director | Appointed | 2022-04-27 |
Leadership
- Jonathan Lim CEO
- David Chacko CFO
- Ebun S. Garner General Counsel
- Alexander W. Casdin Board Member
- James A. Bristol Board Member
- Jean I. Liu Board Member
- Jean Liu, J.D. Board Member
- Julie Hambleton Board Member
- Michael D. Varney Board Member
- Pratik S. Multani Board Member
- Valerie Harding-Start Board Member
Key facts
CIK
1761918
CUSIP
29479A108
13F (30d)
282 filings
260 filers
Visit website
Investor relations